Polygonum multiflorum, especially emodin, may help treat hair loss by targeting specific proteins, offering a new approach beyond traditional therapies.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
22 citations
,
August 2020 in “Cells” TGM3 is important for skin and hair structure and may help diagnose cancer.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
Individualized treatments may help manage Dercum's disease symptoms.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
January 2002 in “대한피부과학회지” Most patients with dermatomyositis had skin rash and were treated with prednisolone and hydroxychloroquine.
7 citations
,
January 2019 in “Dermatology Online Journal” Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
2 citations
,
January 2012 in “PubMed” Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
April 2017 in “Journal of Investigative Dermatology” The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
4 citations
,
October 2023 in “Case Reports in Dermatology” Majocchi’s granuloma should be considered when rashes don't improve with typical treatments.
August 2023 in “Clinical and experimental dermatology and therapies” Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
5 citations
,
September 2024 in “Biomolecules and Biomedicine” Total glucosides of paeony may help treat alopecia areata by reducing inflammation and hair loss.
288 citations
,
January 2001 in “Journal of Biological Chemistry” Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
September 2023 in “Journal of the American Academy of Dermatology” July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
40 citations
,
July 2007 in “Dermatologic Therapy” Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
4 citations
,
January 2009 in “Indian Journal of Dermatology, Venereology and Leprology” A patient with granuloma annulare experienced both isotopic and isomorphic responses, with skin lesions responding to steroids but relapsing after stopping treatment.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.